GSK 6-K
GSK plc (GSK)
6-K
2026-02-11
For: 2026-02-11
View Original
Added on
July 04, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depositary Shares
This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2023 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares and ADS to meet tax liabilities. In accordance with the shareholder approved 2022 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 9 February 2023 and ended on 8 February 2026. The awards vested on 9 February 2026. Dividends accrued on the awards during the restricted period.
The awards were granted in 2023 as restricted awards over ADS for US participants and as nil-cost options over Ordinary Shares for all other participants.
The closing prices of Ordinary Shares and of ADS of GSK plc on 9 February 2026 were £21.59 and $59.01.
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
|---|---|---|---|---|---|
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of an award in the form of a nil-cost option over<br>Ordinary Shares granted in 2023 under the Company's 2017 Deferred<br>Annual Bonus Plan and the subsequent exercise of the nil-cost<br>option | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 60,334 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise<br>of a nil-cost option award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £22.1140 | 4,549 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of an award in the form of a nil-cost option over<br>Ordinary Shares granted in 2023 under the Company's 2017 Deferred<br>Annual Bonus Plan and the subsequent exercise of the nil-cost<br>option | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 25,742 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise<br>of a nil-cost option award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £22.0162 | 13,801 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of an award in the form of a nil-cost option over<br>Ordinary Shares granted in 2023 under the Company's 2017 Deferred<br>Annual Bonus Plan and the subsequent exercise of the nil-cost<br>option | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 25,045 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise<br>of a nil-cost option award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £22.0057 | 11,789 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | The vesting of an award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 12,522 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | The sale of ADS to meet tax liabilities on the vesting of an award<br>granted in 2023 under the Company's 2017 Deferred Annual Bonus<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $59.0729 | 6,497 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | David Redfern | |||
| b) | Position/status | President, Corporate Development | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of an award in the form of a nil-cost option over<br>Ordinary Shares granted in 2023 under the Company's 2017 Deferred<br>Annual Bonus Plan and the subsequent exercise of the nil-cost<br>option | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 34,873 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | David Redfern | |||
| b) | Position/status | President, Corporate Development | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise<br>of a nil-cost option award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £22.0998 | 16,415 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of an award in the form of a nil-cost option over<br>Ordinary Shares granted in 2023 under the Company's 2017 Deferred<br>Annual Bonus Plan and the subsequent exercise of the nil-cost<br>option | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 28,010 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise<br>of a nil-cost option award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £22.0451 | 13,185 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Phil Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of an award in the form of a nil-cost option over<br>Ordinary Shares granted in 2023 under the Company's 2017 Deferred<br>Annual Bonus Plan and the subsequent exercise of the nil-cost<br>option | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 18,321 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Phil Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise<br>of a nil-cost option award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £22.0117 | 8,633 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of an award in the form of a nil-cost option over<br>Ordinary Shares granted in 2023 under the Company's 2017 Deferred<br>Annual Bonus Plan and the subsequent exercise of the nil-cost<br>option | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 44,631 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise<br>of a nil-cost option award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £22.0267 | 21,009 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of an award in the form of a nil-cost option over<br>Ordinary Shares granted in 2023 under the Company's 2017 Deferred<br>Annual Bonus Plan and the subsequent exercise of the nil-cost<br>option | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00<br><br><br> | 21,176 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise<br>of a nil-cost option award granted in 2023 under the Company's 2017<br>Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £22.1186 | 9,978 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: February<br>11, 2026 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |